Biopharmaceutics and Biomaterials

Nearly 70% of all pharmaceutical products are antibody drugs. With the Covid-19 pandemic, mRNA vaccines and related drugs will become the next hot spot in the pharma industry. The production of these biologicals is usually a very complicated and expensive process. Based on the regulation mechanisms of the C1-C3 metabolic system and synthetic biology research, we address key limiting steps of energy and material supplies for large-scale mammalian cell culture, aiming at developing new and economical biomanufacturing processes including intelligent bioreactor and operation techniques with reduced use of expensive raw materials and media.

We are also combining C1-C3 synthetic biology with catalytic soft matter synthetic biology to explore their applications in smart biomaterials and future food (e.g. meat from bioreactor).

Selected literature
1.J Mller, K Bhat, L Guhl, R Prtner, U Jandt, AP Zeng (2020) Lactate metabolism in CHO cells: Investigation of pyruvate dehydrogenase complex regulation. Eng. Life Sci. 21: 100-114.
2.S Hezaveh, AP Zeng, U Jandt (2018) Full Enzyme Complex Simulation: Interactions in Human Pyruvate Dehydrogenase Complex. J. Chem. Inf. Model. 58, 362-369.